// App-Quantinova.ai

: Life Cycle Assessment (LCA and Cradle-to-Grave (CTG Carbon Footprint of a Multidose Reservoir Dry Powder Inhaler

Researchers

Presenter

  • Kristian Borenius

Principal Investigators

  • Ville Vartiainen

  • Aino Takala

  • Jussi Haikarainen

  • Grace Parker

  • Noora Paronen

  • Tari Haahtela

Medical Centers

  • Aalto Univ, Espoo, Finland

  • Orion Pharma, Espoo, Finland

  • Carbon Footprint Ltd, Hampshire, United Kingdom

  • University of Helsinki, H, Finland

Locations

  • Finland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Autoimmune (AI)

Disease

  • Asthma

  • Chronic obstructive pulmonary disease

Biomarkers

  • Protein Tyrosine Phosphatase, Receptor Type C

Drug/Treatment

  • salmeterol + fluticasone

  • budesonide + formoterol fuma

  • DuoResp Spiromax

  • Seretide Accuhaler

  • Tiotropium bromide

  • Fluticasone

  • Azelastine/fluticasone propionate

  • Budesonide

  • Formoterol

  • Salbutamol

  • Salmeterol Xinafoate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved